Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B.

Fensterle J, Bergmann B, Yone CL, Hotz C, Meyer SR, Spreng S, Goebel W, Rapp UR, Gentschev I

Institut für Medizinische Strahlenkunde und Zellforschung, University of Wuerzburg, Wuerzburg, Germany.

Prostate cancer is the most common malignant tumor in men and is normally associated with increased serum levels of prostate-specific antigen (PSA). Therefore, PSA is one potential target for a prostate cancer vaccine. In this study we analyzed the functionality of new bacterial PSA vaccines, expressed and secreted via the hemolysin (HlyA) secretion system of Escherichia coli, the prototype of Type I secretion systems (T1SS) using an attenuated Salmonella enterica serovar Typhimurium aroA strain as carrier. The data demonstrate that a bacterial live vaccine encompassing T1SS in combination with cholera toxin subunit B can be successfully used for delivery of PSA to induce cytotoxic CD8+ T-cell responses resulting in an efficient prevention of tumor growth in mice.

Published 16 January 2008 in Cancer Gene Ther, 15(2): 85-93.
Full-text of this article is available online (may require subscription).

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.